Skip to content

TriSalus Life Sciences, Inc. TLSI Current maturities of long-term debt

Current maturities of long-term debt at other companies

Boston Scientific logo
Boston ScientificBSX
AngioDynamics logo
AngioDynamicsANGO
Novanta logo
NovantaNOVT
Plexus logo
PlexusPLXS

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%
Debt / equity2.6×
Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: TriSalus Life Sciences, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s current maturities of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s current maturities of long-term debt?
TriSalus Life Sciences, Inc. (TLSI) reported current maturities of long-term debt of $39K in Q4 2025.
What is the long-term trend for TriSalus Life Sciences, Inc.'s current maturities of long-term debt?
Over 2 years (2023 to 2025), TriSalus Life Sciences, Inc.'s current maturities of long-term debt has grown at a -28.4% compound annual growth rate (CAGR), from $76K to $39K.